Vildagliptin: The evidence for its place in the treatment of type 2 diabetes mellitus

Core Evidence

Volumn 3, Issue 1, 2008, Pages 13-30

  Profit, Louise ^a   Chrisp, Paul ^a   Nadin, Carole ^a  

^a Mere House ^*  (United Kingdom)

Author keywords

Dipeptidyl peptidase IV (dipeptidyl peptidase 4) inhibition; Glycemic control; LAF 237; Type 2 diabetes; Vildagliptin

Indexed keywords

EID: 80052913268     PISSN: 15551741     EISSN: None     Source Type: Journal    
DOI: 10.3355/ce.2008.009     Document Type: Review

References (95)

1. AACE (American Association of Clinical Endocrinologists). Diabetic Guidelines. Endocrine Practice. 2002;8(Suppl 1):41-65.
2. AACE (American Association of Clinical Endocrinologists). State of Diabetes in America. Available at: http://www.stateofdiabetes.com (accessed November 8, 2005).
3. ACCORD Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-2559.
4. ADA (American Diabetes Association) and NIDDKD (National Institute of Diabetes, Digestive and Kidney Diseases). The prevention or delay of type 2 diabetes. Diabetes Care. 2002;25:742-749.
5. ADA (American Diabetes Association). Standards of medical care in diabetes. Diabetes Care. 2005;28(Suppl. 1):S4-S36.
6. Ahrén B, Landin-Olsson M, Jansson P-A, et al. The DPPIV inhibitor, LAF237, reduces fasting and postprandial glucose in subjects with type 2 diabetes over a 4 week period by increasing active GLP-1, sustaining insulin and reducing glucagon. Diabetes. 2003;52 (Suppl. 1):A15. Abstract 65-OR.
7. Ahrén B, Mills D, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care. 2004a;27:2874-2880. (Pubitemid 39565052)
8. Ahrén B, Landin-Olsson M, Jansson P-A, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagons levels in type 2 diabetes. J Clin Endocrinol Metab. 2004b;89:2078-2084. (Pubitemid 38619835)
9. Ahrén B, Gomis R, Mills D, Schweizer A. The DPP-4 inhibitor, LAF237, improves glycemic control in patients with type 2 diabetes (T2DM) inadequately treated with metformin. Presented at the American Diabetes Association Scientific Sessions, 2004c. Abstract 354-OR. Available at: http://scientificsessions.diabetes.org/Abstracts/index.cfm (accessed December 12, 2005).
10. Ahrén B, Winzell MS, Burkey B, Hughes TE. Beta-cell expression of a dominant-negative hepatocyte nuclear factor (HNF)-1alfa compromises the ability of DPP-4 inhibition to elicit a long-term augmentation of insulin secretion in mice. Presented at the American Diabetes Association Scientific Sessions, 2005a. Abstract 1559-P. Available at: http://scientificsessions. diabetes.org/Abstracts/index.cfm (accessed December 12, 2005).
11. Ahrén B, Foley JE, Pacin G, Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care. 2005b;28:1936-1940. (Pubitemid 41060966)
12. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298:194-206. (Pubitemid 47057766)
13. Anon. New Galvus® clinical data reinforces efficacy profile; safety update provided to regulatory agencies. Available at http://cws.huginonline.com/ N/134323/PR/200711/1166139-5-2.html (accessed November 12, 2007).
14. Barilla D, He Y, Balez S, et al. No pharmacokinetic interactions or acute clinical safety issues preclude combination of the DPP-4 inhibitor LAF237 with glyburide. Presented at the American Diabetes Association Scientific Sessions, 2004. Abstract 1967-PO. Available at: http://scientificsessions.diabetes.org/ Abstracts/index.cfm (accessed December 12, 2005).
15. Baron MA, Rosenstock J, Bassiri B, et al. Efficacy of vildagliptin combined with pioglitazone in patients with type 2 diabetes. Presented at the European Association for the Study of Diabetes Annual Meeting, 2006. Abstract 0801. Available at: http://www.easd.org/ (accessed October 11, 2007).
16. Bartnik M, Malmberg K, Norhammar A, Tenerz A, Ohrvik J, Rydén L. Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur Heart J. 2004;25:1990-1997. (Pubitemid 39486017)
17. Bloomgarden ZT. Type 2 diabetes in the young: the evolving epidemic. Diabetes Care. 2004;27:998-1010. (Pubitemid 38420231)
18. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care. 2007;30:890-895. (Pubitemid 46556583)
19. Brandt I, Joossens J, Chen X, et al. Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by vildagliptin ((2S)-{[3-hydroxyadamantan-1-yl) amino]acetyl]}- pyrrolidine-2-carbonitrile). Biochem Pharmacol. 2005;70:134-143. (Pubitemid 40797877)
20. Burkey B, Li X, Bolognese L, et al. Combination treatment of a DPP-IV inhibitor NVP-LAF237 with pioglitazone completely normalized glucose tolerance in adult obese Zucker rats. Diabetes. 2002;51(Suppl. 2):A338. Abstract 1383-P.
21. Burkey BP, Li X, Bolognese L, et al. Acute and chronic effects of the incretin enhancer vildagliptin in insulin resistant rats. J Pharmacol Exp Ther. 2005;315:688-695. (Pubitemid 41500734)
22. CDC (Centers for Disease Control and Prevention). Diabetes Projects, 2005b. Available at: http://www.cdc.gov/diabetes/projects/cda2.htm (accessed November 7, 2005).
23. CDC (Centers for Disease Control and Prevention). Fact Sheet. SEARCH for Diabetes in Youth, 2005a. Available at: http://www.cdc.gov/diabetes/pubs/pdf/ search.pdf (accessed November 7, 2005).
24. CDC (Centers for Disease Control and Prevention). National Diabetes Fact Sheet, United States, 2003. General Information. Available at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2003.pdf (accessed November 7, 2005).
25. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072-2077. (Pubitemid 34680970)
26. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999;22:233-240. (Pubitemid 29056916)
27. Dardik B, Schwartzkopf C, Stevens D, et al.The dipeptidyl peptidase IV inhibitor NVP-LAF237 improves metabolic control in diabetic and nondiabetic cynomolgus monkeys. Diabetes. 2003a;52(Suppl.1):A322. Abstract 1391-P.
28. Dardik B, Valentin M, Schwartzkopf C, et al. NVP-LAF237, a dipeptidyl peptidase IV inhibitor, improves glucose tolerance and delays gastric emptying in obese insulin resistant cynomolgus monkeys. Diabetes. 2003b;52 (Suppl.1):A322. Abstract 1392-P.
29. DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001;161:397-405.
30. Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res. 2007a;39:218-223. (Pubitemid 46580622)
31. Dejager S, Schweizer A, Couturier A, Pratley RE. Achievement of glycaemic targets with vildagliptin. Presented at the European Association for the Study of Diabetes Annual Meeting, 2007b. Abstract 0885. Available at: http://www.easd.org/ (accessed October 11, 2007).
32. Duttaroy A, Voelker F, Merriam K, Zhang X, Ren X, Burkey B. The DPP-4 inhibitor vildagliptin increases pancreatic beta-cell neogenesis and decreases apoptosis. Presented at the American Diabetes Association Scientific Sessions, 2005a. Abstract 572-P. Available at: http://scientificsessions. diabetes.org/Abstracts/index.cfm (accessed December 12, 2005).
33. Duttaroy A, Voelker F, Ren X, et al. Head-to-head comparison of the DPP-4 inhibitor vildagliptin with exendin-4 in a model of pancreatic beta-cell injury. Presented at the American Diabetes Association Scientific Sessions, 2005b. Abstract 267-OR. Available at: http://scientificsessions.diabetes.org/ Abstracts/index.cfm (accessed December 12, 2005).
34. EDPG (European Diabetes Policy Group). A desktop guide to type 2 diabetes. International Diabetes Federation European Region. Diabetic Med. 1999;16:716-730.
35. El-Ouaghlidi A, Rehring E, Holst JJ, Schweizer A, Holmes D, Nauck MA. Reduced increments in total glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) in plasma after a single dose of the dipeptidyl peptidase-4 inhibitor LAF237 before an oral glucose load in healthy subjects. Presented at the European Association for the Study of Diabetes Annual Meeting, 2004. Abstract 786. Available at: http://212.144.4.93/easd/UpApplications/ UpTables/provisionalprogram/groupviewpage.asp (accessed December 12, 2005).
36. El-Ouaghlidi A, Rehring E, Schweizer A, Holmes D, Nauck M. The dipeptidyl peptidase IV inhibitor LAF 237 does not accentuate reactive hypoglycemia caused by the sulfonylurea glibenclamide administered before an oral glucose load in healthy subjects. Diabetes. 2003;52 (Suppl. 1):A118. Abstract 507-P.
37. Fonseca V, Dejager S, Albrecht D, Shao Q, Schweizer A. Sustained efficacy and reduced hypoglycaemia with vildagliptin added to insulin in patients with type 2 diabetes. Presented at the European Association for the Study of Diabetes Annual Meeting, 2006. Abstract 0802. Available at: http://www.easd.org/ (accessed October 11, 2007).
38. Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia. 2007;50:1148-1155. (Pubitemid 46701545)
39. Fox CS, Larson MG, Leip EP, Meigs JB, Wilson PW, Levy D. Glycemic status and development of kidney disease: the Framingham Heart Study. Diabetes Care. 2005;28:2436-2440. (Pubitemid 41384290)
40. Garber AJ, Camisasca R-P, Jauffret S, Baron MA. Efficacy and tolerability of vildagliptin added to a sulfonylurea (SU) in patients with type 2 diabetes (T2DM). Presented at the American Diabetes Association Annual Meeting, 2007a. Abstract 0501-P. Available at: http://scientificsessions.diabetes.org/Abstracts/ index.cfm (accessed October 11, 2007).
41. Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes, Obesity and Metabolism. 2007b;9:166-174. (Pubitemid 46206560)
42. Goeke B, Schweizer A, Couturier A, LeBeaut A, Dejager S. Sustained efficacy and tolerability of vildagliptin monotherapy during one-year treatment of drug-naïve patients with type 2 diabetes. Presented at the European Association for the Study of Diabetes Annual Meeting, 2006. Abstract 0042. Available at: http://www.easd.org/ (accessed October 11, 2007).
43. Gray A, Raikou M, McGuire A, et al; United Kingdom Prospective Diabetes Study Group. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). BMJ. 2000;320:1373-1378. (Pubitemid 30261117)
44. Hjøllund KR, Hughes TE, Holst JJ. The dipeptidyl peptidase 4 inhibitor vildagliptin has no acute effect on the endocrine secretion in the isolated perfused porcine pancreas. Presented at the European Association for the Study of Diabetes Annual Meeting, 2007. Abstract 0691. Available at: http://www.easd.org/ (accessed March 4, 2008).
45. Hogan P, Dall T, Nikolov P; American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care. 2003;26:917-932.
46. Holman RR. Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. Diabetes Res Clin Pract. 1998;40(Suppl):S21-S25. (Pubitemid 28370886)
47. Holst JJ, Deacon CF. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia. 2005;48:612-615. (Pubitemid 40591213)
48. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab. 2004;287:E199-E206. (Pubitemid 38943883)
49. Hughes TE, Russell ME, Bolognese L, et al. NVP-LAF237, a highly selective and long-acting dipeptidyl peptidase IV inhibitor. Diabetes. 2002;51(Suppl. 2):A67. Abstract 272-OR.
50. IDF (International Diabetes Federation). Diabetes Prevelance. 2005a. Available at http://www.idf.org/home/index.cfm?node=264 (accessed November 7, 2005).
51. IDF. Global guideline for type 2 diabetes. 2005b. Available at http://www.idf.org/home/index.cfm?node=1457 (accessed October 16, 2007).
52. Jellinger PS, Davidson JA, Blonde L, et al. Road maps to achieve glycemic control in type 2 diabetes mellitus: ACE/AACE Diabetes Road Map Task Force. Endocr Pract. 2007;13:260-268.
53. Jonsson B. CODE-2 Advisory Board. Revealing the cost of Type II diabetes in Europe. Diabetologia. 2002;45:S5-S12. (Pubitemid 34762208)
54. Kahn R, Buse J, Ferrannini E, Stern M; American Diabetes Association; European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005;28:2289-2304. (Pubitemid 41242486)
55. Kelley DE, Dunning BE, Ligueros-Saylan M, Holst JJ, Deacon CF, Foley JE. Four-week treatment with vildagliptin increases fasting plasma levels of intact incretin hormones both in patients with type 1 (T1DM) and type 2 (T2DM) diabetes. Presented at the American Diabetes Association Annual Meeting, 2006. Abstract 1481-P. Available at: http://scientificsessions.diabetes.org/ Abstracts/index.cfm (accessed October 11, 2007).
56. Kikuchi M, Abe N, Kato M, Terao S, Holmes D, Mimori N. Vildagliptin decreases HbA1c after 12 weeks treatment in Japanese patients with type 2 diabetes. Presented at the European Association for the Study of Diabetes Annual Meeting, 2006. Abstract 0789. Available at: http://www.easd.org/ (accessed October 11, 2007).
57. Kimmel B, Inzucchi SE. Oral agents for type 2 diabetes: an update. Clinical Diabetes. 2005;23:64-76. (Pubitemid 40965047)
58. Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403. (Pubitemid 34437694)
59. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27:17-20.
60. Mari A, Sallas M, He YL, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab. 2005;90:4888-4894. (Pubitemid 41159387)
61. Mika A, Stashko M, Lubben T, et al. Acute DPP-IV inhibition minimizes glucose and insulin responses to a glucose challenge in a diabetic mouse. Presented at the American Diabetes Association Scientific Sessions, 2003. Abstract 1516-P. Available at: http://scientificsessions.diabetes.org/Abstracts/ index.cfm (accessed December 12, 2005).
62. Mimori N, Terao S, Holmes D. Vildagliptin improves glucose control as evidenced by HbA1c after 12 weeks therapy in Japanese patients with type 2 diabetes. Presented at the American Diabetes Association Annual Meeting, 2006. Abstract 527-P. Available at: http://scientificsessions.diabetes.org/Abstracts/ index.cfm (accessed October 11, 2007).
63. Nauck MA, El-Ouaghlidi A. The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1. Diabetologia. 2005;48:608-611. (Pubitemid 40591212)
64. Nauck M, Stockmann F, Ebert R, et al. Reduced incretin effect in type 2 (non-insulin dependent) diabetes. Diabetologia. 1986;29:46-52. (Pubitemid 16162741)
65. Nauck MA, Wollschlager D, Werner J, et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1[7-36 amide]) in patients with NIDDM. Diabetologia. 1996;39:1546-1553. (Pubitemid 26397366)
66. NICE (National Institute for Health and Clinical Excellence). Clinical guidelines for type 2 diabetes: Management of blood glucose. September 2002. Available at: http://www.nice.org.uk (accessed November 7, 2005).
67. Pan XR, Li GW, Hu YH, et al; The Da Qing IGT and Diabetes Study. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. Diabetes Care. 1997;20:537-544.
68. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. Diabetes Res Clin Pract. 2007;76:132-138. (Pubitemid 46240373)
69. Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr. 2005;146:693-700. (Pubitemid 40616257)
70. Pratley R, Galbreath E. Twelve-week monotherapy with the DPP-4 inhibitor LAF237 improves glycemic control in patients with type 2 diabetes. Diabetes. 2004;53(Suppl. 2):A83. Abstract 355-OR.
71. Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res. 2006;38:423-428. (Pubitemid 44047965)
72. Pratley RE, Rosenstock J, Pi-Sunyer FX, Couturier A, Schweizer A, Dejager S. Efficacy and safety of vildagliptin in the elderly: pooled analysis of 5 monotherapy studies. Presented at the European Association for the Study of Diabetes Annual Meeting, 2007b. Abstract 0887. Available at: http://www.easd.org/ (accessed October 11, 2007).
73. Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab. 2005;7:692-698. (Pubitemid 41601073)
74. Rolin B, Nygaard H, Wilken M, Kanstrup AB, Carr RD. The novel, xanthine-based, DPPIV inhibitor NN7201 and LAF237 improve glucose tolerance but do not prevent progression of diabetes in Zucker diabetic fatty rats. Presented at the American Diabetes Association Scientific Sessions, 2004. Abstract 1417-P. Available at: http://scientificsessions.diabetes.org/Abstracts/index.cfm (accessed December 12, 2005).
75. Rosenstock J, Baron MA, Camisasca RP, Cressier F, Cautier A, Dejager S. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2007a;9:175-185. (Pubitemid 46206561)
76. Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes. Diabetes Care. 2007b;30:217-223. (Pubitemid 46198322)
77. Rosenstock J, Rendell MS, Landin-Olsson M, Foley JE, Rochette E, Baron MA, Dejager S. Effects of vildagliptin in subjects with IGT. Presented at the American Diabetes Association Annual Meeting, 2007c. Abstract 0505-P. Available at: http://scientificsessions.diabetes.org/Abstracts/index.cfm (accessed October 11, 2007).
78. Rosenstock J, Pi-Sunyer FX, Banerji MA, Couturier A, Schweizer A, Dejager S. Consistent efficacy and safety of vildagliptin monotherapy across ethnicities. Presented at the American Diabetes Association Annual Meeting, 2007d. Abstract 2141-PO. Available at: http://scientificsessions.diabetes.org/ Abstracts/index.cfm (accessed October 11, 2007).
79. Saydah SH, Eberhardt MS, Loria CM, Brancati FL. Subclinical states of glucose intolerance and risk of death in the US. Diabetes Care. 2001;24:447-453. (Pubitemid 32198411)
80. Scherbaum WA, Schweizer A, Mari A, et al. Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes (T2DM) and mild hyperglycemia. Presented at the American Diabetes Association Annual Meeting, 2007. Abstract 0503-P. Available at: http://scientificsessions.diabetes.org/ Abstracts/index.cfm (accessed October 11, 2007).
81. Schweizer A, Couturiert A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Med. 2007;24:955-961. (Pubitemid 47301637)
82. Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141:421-431.
83. Serra DB, He Y-L, Wang Y, et al. Combination of the DPP-4 inhibitor vildagliptin (LAF237) with pioglitazone is safe and well tolerated with no pharmacokinetic interaction. Presented at the American Diabetes Association Scientific Sessions, 2005. Abstract 2192-PO. Available at: http:// scientificsessions. diabetes.org/Abstracts/index.cfm (accessed December 12, 2005).
84. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005;365:1333-1346.
85. Thuren T, Byiers S, Mohideen P. Vildagliptin is safe and well tolerated in patients with mild or moderate renal impairment. Presented at the European Association for the Study of Diabetes Annual Meeting, 2007. Abstract 0881. Available at: http://www.easd.org/ (accessed October 11, 2007).
86. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155-161. Erratum in: Diabetes Care. 2004;27:856. (Pubitemid 38280575)
87. Tuomilehto J, Lindström J, Eriksson JG, et al; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350. (Pubitemid 32378388)
88. Turner RC, Cull CA, Frighi V, Homan R; The UKPDS Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS49). JAMA. 1999;281:2005-2012. (Pubitemid 29254858)
89. UKPDS (UK Prospective Diabetes Study) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998a;352:854-865.
90. UKPDS (UK Prospective Diabetes Study) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998b;352:837-853.
91. Utzschneider KM, Tong J, Udayasankar J, et al. The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves insulin sensitivity and beta-cell function in subjects with impaired fasting glucose. Presented at the American Diabetes Association Annual Meeting, 2007. Abstract 0515-P. Available at: http://scientificsessions.diabetes.org/Abstracts/index.cfm (accessed October 11, 2007).
92. Vella A, Bock G, Giesler PD, et al. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes. 2007;56:1475-1480. (Pubitemid 46715627)
93. Villhauer EB, Brinkman JA, Naderi GB, et al. 1-[[(3-hydroxy-1-adamantyl) amino] acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem. 2003;46:2774-2789. (Pubitemid 36702545)
94. WHO (World Health Organization). Screening for type 2 diabetes. Report of a World Health Organization and International Federation Meeting 2003. Available at http://www.who.int/diabetes/publications/en/screening-mnc03.pdf (accessed November 7, 2005).
95. Zander M, Madsbad S, Madsen JL, Holst J. Effect of a 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002;359:824-830. (Pubitemid 34233752)